Advertisement

Uterine Cancer pp 201-221 | Cite as

Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas: Treatment of Choice Is Combined Chemotherapy and Radiation

  • Laura M. Divine
  • Matthew A. PowellEmail author
Part of the Current Clinical Oncology book series (CCO)

Abstract

The entities covered in this chapter are uterine serous carcinoma (USC), carcinosarcoma, and clear-cell carcinoma together with tumors of mixed histology. Overall, these represent 3–10 % of all endometrial cancers but they are responsible for a significant percentage of endometrial cancer mortality. Recent strides in chemotherapy for some of these cancers offer hope that their addition, either alone or as a part of combined modality treatment including radiation, will lead to improvements in survival.

Keywords

Uterine serous Carcinosarcoma Clear cell Chemotherapy Chemoradiation 

References

  1. 1.
    American Cancer Society. Cancer facts and figures 2015. Atlanta: G.A.C.S; 2015.Google Scholar
  2. 2.
    Hamilton CA et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–6.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med. 1981;105(11):615–8.PubMedGoogle Scholar
  4. 4.
    Hendrickson M et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93–108.PubMedGoogle Scholar
  5. 5.
    Kato DT et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59(3):384–9.PubMedGoogle Scholar
  6. 6.
    Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54(2):278–91.PubMedGoogle Scholar
  7. 7.
    Cirisano Jr FD et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77(1):55–65.PubMedGoogle Scholar
  8. 8.
    Fader AN et al. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22(1):21–9.PubMedGoogle Scholar
  9. 9.
    Platz CE, Benda JA. Female genital tract cancer. Cancer. 1995;75(1 Suppl):270–94.PubMedGoogle Scholar
  10. 10.
    Grice J et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69(1):69–73.PubMedGoogle Scholar
  11. 11.
    Goff BA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54(3):264–8.PubMedGoogle Scholar
  12. 12.
    Bristow RE et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol. 2001;81(2):279–86.PubMedGoogle Scholar
  13. 13.
    Tay EH, Ward BG. The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing? Int J Gynecol Cancer. 1999;9(6):463–9.PubMedGoogle Scholar
  14. 14.
    Abramovich D et al. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J Cancer Res Clin Oncol. 1999;125(12):697–8.PubMedGoogle Scholar
  15. 15.
    Gupta D et al. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. Int J Gynecol Cancer. 2011;21(3):529–34.PubMedGoogle Scholar
  16. 16.
    Olawaiye AB et al. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol. 2008;110(3):293–8.PubMedGoogle Scholar
  17. 17.
    Boruta 2nd DM et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer. 2004;101(10):2214–21.PubMedGoogle Scholar
  18. 18.
    Bjorge T et al. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007;120(2):378–83.PubMedGoogle Scholar
  19. 19.
    Gehrig PA et al. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208–11.PubMedGoogle Scholar
  20. 20.
    Chan JK et al. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol. 2006;102(3):508–12.PubMedGoogle Scholar
  21. 21.
    Geisler JP et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol. 2001;83(3):501–3.PubMedGoogle Scholar
  22. 22.
    Barakat RR et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994;55(2):164–8.PubMedGoogle Scholar
  23. 23.
    Bergman L et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 2000;356(9233):881–7.PubMedGoogle Scholar
  24. 24.
    Fisher B et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.PubMedGoogle Scholar
  25. 25.
    Magriples U et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11(3):485–90.PubMedGoogle Scholar
  26. 26.
    Mignotte H et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer. 1998;76(3):325–30.PubMedGoogle Scholar
  27. 27.
    Saadat M et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer. 2007;110(1):31–7.PubMedGoogle Scholar
  28. 28.
    Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol. 1994;13(3):248–58.PubMedGoogle Scholar
  29. 29.
    Goshen R et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000;79(3):477–81.PubMedGoogle Scholar
  30. 30.
    Lavie O et al. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol. 2000;96(1):28–32.PubMedGoogle Scholar
  31. 31.
    Low JS et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol. 2005;97:171–7.PubMedGoogle Scholar
  32. 32.
    Fakiris AJ et al. Intraperitoneal radioactive phosphorous (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience. Brachytherapy. 2010;9(1):61–5.PubMedGoogle Scholar
  33. 33.
    Levine DA et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 2001;80(3):395–8.PubMedGoogle Scholar
  34. 34.
    Boruta 2nd DM et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115(1):142–53.PubMedGoogle Scholar
  35. 35.
    Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444(3):213–23.PubMedGoogle Scholar
  36. 36.
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.PubMedGoogle Scholar
  37. 37.
    El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev Anticancer Ther. 2012;12(1):41–9.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Fader AN, Santin AD, Gehrig PA. Early stage uterine serous carcinoma: management updates and genomic advances. Gynecol Oncol. 2013;129(1):244–50.PubMedGoogle Scholar
  39. 39.
    Cancer Genome Atlas Research Network et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.Google Scholar
  40. 40.
    Slomovitz BM et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463–9.PubMedGoogle Scholar
  41. 41.
    Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control. 2009;16(1):46–52.PubMedGoogle Scholar
  42. 42.
    Chan JK et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 2003;90(1):181–5.PubMedGoogle Scholar
  43. 43.
    Geisler JP et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol. 1999;74(3):465–7.PubMedGoogle Scholar
  44. 44.
    ASTEC Study Group et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.Google Scholar
  45. 45.
    Growdon WB et al. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012;22(3):417–24.PubMedGoogle Scholar
  46. 46.
    Turner BC et al. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int J Radiat Oncol Biol Phys. 1998;40(1):77–84.PubMedGoogle Scholar
  47. 47.
    Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47(3):298–305.PubMedGoogle Scholar
  48. 48.
    Fader AN et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115(2):244–8.PubMedGoogle Scholar
  49. 49.
    Lim P et al. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer. 2001;91(4):752–7.PubMedGoogle Scholar
  50. 50.
    Sood BM et al. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2003;57(1):208–16.PubMedGoogle Scholar
  51. 51.
    Mehta N et al. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;57(4):1004–9.PubMedGoogle Scholar
  52. 52.
    Keys HM et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51.PubMedGoogle Scholar
  53. 53.
    Havrilesky LJ et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;105(3):677–82.PubMedGoogle Scholar
  54. 54.
    Kwon J, Ackerman I, Franssen E. The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2004;59(5):1439–45.PubMedGoogle Scholar
  55. 55.
    Martinez AA et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecol Oncol. 2003;90(3):537–46.PubMedGoogle Scholar
  56. 56.
    Sutton G et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):349–54.PubMedGoogle Scholar
  57. 57.
    Huh WK et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol. 2003;91(3):470–5.PubMedGoogle Scholar
  58. 58.
    Hamilton CA et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2005;63(3):839–44.PubMedGoogle Scholar
  59. 59.
    Thomas MB et al. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;107(2):186–9.PubMedGoogle Scholar
  60. 60.
    Kiess AP et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol. 2012;127(2):321–5.PubMedGoogle Scholar
  61. 61.
    Kelly MG et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005;98(3):353–9.PubMedGoogle Scholar
  62. 62.
    Abeler VM et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78(8):1740–7.PubMedGoogle Scholar
  63. 63.
    Hogberg T, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol (Meeting Abstracts). 2007; 25(18_suppl): 5503.Google Scholar
  64. 64.
    Elit L et al. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol. 2004;92(1):240–6.PubMedGoogle Scholar
  65. 65.
    Dietrich 3rd CS et al. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2005;99(3):557–63.PubMedGoogle Scholar
  66. 66.
    Ramondetta L et al. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001;82(1):156–61.PubMedGoogle Scholar
  67. 67.
    Miller D et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125:771–3.Google Scholar
  68. 68.
    Rosenberg P et al. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol. 1993;51(3):311–5.PubMedGoogle Scholar
  69. 69.
    Fields AL et al. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2008;108(1):201–6.PubMedGoogle Scholar
  70. 70.
    Fader AN et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol. 2009;112(3):558–62.PubMedGoogle Scholar
  71. 71.
    Hogberg T et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010;46(13):2422–31.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Scully RE, Barlow JF. "Mesonephroma" of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma. Cancer. 1967;20(9):1405–17.PubMedGoogle Scholar
  73. 73.
    Kanbour-Shakir A, Tobon H. Primary clear cell carcinoma of the endometrium: a clinicopathologic study of 20 cases. Int J Gynecol Pathol. 1991;10(1):67–78.PubMedGoogle Scholar
  74. 74.
    Craighead PS et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol. 2000;77(2):248–53.PubMedGoogle Scholar
  75. 75.
    Cirisano Jr FD et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74(3):385–94.PubMedGoogle Scholar
  76. 76.
    Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982;49(8):1511–23.PubMedGoogle Scholar
  77. 77.
    Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40(3):207–17.PubMedGoogle Scholar
  78. 78.
    Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol. 1995;14(1):30–8.PubMedGoogle Scholar
  79. 79.
    Creasman WT et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95(3):593–6.PubMedGoogle Scholar
  80. 80.
    McMeekin DS et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;106(1):16–22.PubMedGoogle Scholar
  81. 81.
    Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol. 1990;14(4):317–28.PubMedGoogle Scholar
  82. 82.
    Kounelis S et al. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol. 1998;29(1):82–7.PubMedGoogle Scholar
  83. 83.
    Emoto M et al. Characteristics of cloned cells of mixed mullerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro. Cancer. 1993;71(10):3065–75.PubMedGoogle Scholar
  84. 84.
    Wada H et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997;57(23):5379–85.PubMedGoogle Scholar
  85. 85.
    Fujii H et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 2000;60(1):114–20.PubMedGoogle Scholar
  86. 86.
    Silverberg SG et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9(1):1–19.PubMedGoogle Scholar
  87. 87.
    Fleming WP et al. Autopsy findings in patients with uterine sarcoma. Gynecol Oncol. 1984;19(2):168–72.PubMedGoogle Scholar
  88. 88.
    Amant F et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol. 2005;98(2):274–80.PubMedGoogle Scholar
  89. 89.
    Gadducci A et al. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129–42.PubMedGoogle Scholar
  90. 90.
    Brooks SE et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93(1):204–8.PubMedGoogle Scholar
  91. 91.
    Inthasorn P et al. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer. 2002;12(4):348–53.PubMedGoogle Scholar
  92. 92.
    McCluggage WG et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer. 2000;10(4):280–4.PubMedGoogle Scholar
  93. 93.
    Major FJ et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71(4 Suppl):1702–9.PubMedGoogle Scholar
  94. 94.
    Nielsen SN et al. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol. 1989;34(3):372–8.PubMedGoogle Scholar
  95. 95.
    Ramondetta LM et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003;90(3):529–36.PubMedGoogle Scholar
  96. 96.
    Yamada SD et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88(12):2782–6.PubMedGoogle Scholar
  97. 97.
    NCCN clinical practice guidelines in oncology. Uterine neoplasms, version 2.2016. National Comprehensive Cancer Network (2015).Google Scholar
  98. 98.
    Schiavone MB et al. Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol. 2016;23(1):196–202.PubMedGoogle Scholar
  99. 99.
    Wolfson AH et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107(2):177–85.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Page BR et al. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology. Int J Gynecol Cancer. 2012;22(4):593–8.PubMedGoogle Scholar
  101. 101.
    Reed NS et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18.PubMedGoogle Scholar
  102. 102.
    Omura GA et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3(9):1240–5.PubMedGoogle Scholar
  103. 103.
    Cantrell LA et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012;127(1):22–6.PubMedGoogle Scholar
  104. 104.
    del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012;127(3):651–61.PubMedGoogle Scholar
  105. 105.
    Brown LC et al. Vaginal brachytherapy for early-stage carcinosarcoma of the uterus. Brachytherapy. 2015;14(4):433–9.PubMedGoogle Scholar
  106. 106.
    Gerszten K et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998;68(1):8–13.PubMedGoogle Scholar
  107. 107.
    Knocke TH et al. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol. 1999;73(3):389–95.PubMedGoogle Scholar
  108. 108.
    Chi DS et al. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997;65(3):493–8.PubMedGoogle Scholar
  109. 109.
    Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol. 2001;27(3):282–5.PubMedGoogle Scholar
  110. 110.
    Sutton G et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96(3):630–4.PubMedGoogle Scholar
  111. 111.
    Resnik E et al. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus. Gynecol Oncol. 1995;56(3):370–5.PubMedGoogle Scholar
  112. 112.
    Odunsi K et al. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up. Int J Gynecol Cancer. 2004;14(4):659–64.PubMedGoogle Scholar
  113. 113.
    Molpus KL et al. Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors. Eur J Gynaecol Oncol. 1998;19(6):541–6.PubMedGoogle Scholar
  114. 114.
    Callister M et al. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004;58(3):786–96.PubMedGoogle Scholar
  115. 115.
    Sartori E et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol. 1997;67(1):70–5.PubMedGoogle Scholar
  116. 116.
    Sutton GP et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1989;161(2):309–12.Google Scholar
  117. 117.
    Sutton G et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol. 2000;79(2):147–53.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Curtin JP et al. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2001;83(2):268–70.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Miller DS et al. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;98(2):217–21.PubMedGoogle Scholar
  120. 120.
    Homesley HD et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526–31.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Toyoshima M et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol. 2004;94(3):774–8.PubMedGoogle Scholar
  122. 122.
    Powell MA et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010;28(16):2727–31.PubMedPubMedCentralGoogle Scholar
  123. 123.
    Kohorn EI et al. Adjuvant therapy in mixed mullerian tumors of the uterus. Gynecol Oncol. 1986;23(2):212–21.PubMedGoogle Scholar
  124. 124.
    Manolitsas TP et al. Multimodality therapy for patients with clinical Stage I and II malignant mixed Mullerian tumors of the uterus. Cancer. 2001;91(8):1437–43.PubMedGoogle Scholar
  125. 125.
    Menczer J et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005;97(1):166–70.PubMedGoogle Scholar
  126. 126.
    Fakiris AS et al. Intraperitoneal radioactive phosphorous and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma the Indiana University experience. Brachytherapy, 2010. 9(1)61–5.PubMedGoogle Scholar
  127. 127.
    Low US et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol. 2005;97:171–177.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Division of Gynecologic Oncology, Department of Obstetrics and GynecologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations